Serotonin and Parkinson's disease: On movement, mood, and madness
Identifieur interne : 001F59 ( Main/Exploration ); précédent : 001F58; suivant : 001F60Serotonin and Parkinson's disease: On movement, mood, and madness
Auteurs : Susan H. Fox [Canada] ; Rosalind Chuang [Canada] ; Jonathan M. Brotchie [Canada]Source :
- Movement Disorders [ 0885-3185 ] ; 2009-07-15.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- 5‐HT, Affect (physiology), Animals, Anxiety, Constipation, Depression, Dyskinesia, Dyskinesia, Drug-Induced, Humans, Mental Disorders (complications), Mental Disorders (metabolism), Mood, Movement (physiology), Nervous system diseases, Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Parkinson Disease (physiopathology), Parkinson disease, Parkinson's disease, Psychosis, Serotonin, Serotonin (metabolism), Serotonin Agents (adverse effects), Serotonin Agents (therapeutic use), anxiety, constipation, depression, dyskinesia, psychosis, serotonin.
- MESH :
- chemical , adverse effects : Serotonin Agents.
- chemical , metabolism : Serotonin.
- complications : Mental Disorders.
- drug therapy : Parkinson Disease.
- metabolism : Mental Disorders, Parkinson Disease.
- physiology : Affect, Movement.
- physiopathology : Parkinson Disease.
- chemical , therapeutic use : Serotonin Agents.
- Animals, Dyskinesia, Drug-Induced, Humans.
Abstract
An appreciation of the multiple roles that serotonin (5‐HT) may play in Parkinson's disease (PD) has increased in recent years. Early pathological studies in PD demonstrated nonselective reductions of 5‐HT in brain tissue but little correlation to comorbidities such as dyskinesia and mood disturbance. This, combined with treatment failures using serotonergic drugs in comparison to levodopa, meant the field was largely neglected until recently. The multitude of subtypes of 5‐HT receptors in the brain and an increased understanding of the potential function 5‐HT may play in modulating other neurotransmitter systems, including dopamine, GABA, and glutamate, have meant an expansion in efforts to develop potential serotonergic drugs for both motor and nonmotor symptoms in PD. However, several unanswered questions remain, and future studies need to focus on correlating changes in 5‐HT neurotransmission in both pathological and in vivo imaging studies with a full clinical phenotype. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22473
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000238
- to stream Istex, to step Curation: 000238
- to stream Istex, to step Checkpoint: 000735
- to stream PubMed, to step Corpus: 000E54
- to stream PubMed, to step Curation: 000E54
- to stream PubMed, to step Checkpoint: 000E54
- to stream Ncbi, to step Merge: 000A75
- to stream Ncbi, to step Curation: 000A75
- to stream Ncbi, to step Checkpoint: 000A75
- to stream Main, to step Merge: 002112
- to stream PascalFrancis, to step Corpus: 000525
- to stream PascalFrancis, to step Curation: 000767
- to stream PascalFrancis, to step Checkpoint: 000418
- to stream Main, to step Merge: 002222
- to stream Main, to step Curation: 001F59
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Serotonin and Parkinson's disease: On movement, mood, and madness</title>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
</author>
<author><name sortKey="Chuang, Rosalind" sort="Chuang, Rosalind" uniqKey="Chuang R" first="Rosalind" last="Chuang">Rosalind Chuang</name>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:E7D9C00B982C39FA601C49360BD62531C9418656</idno>
<date when="2009" year="2009">2009</date>
<idno type="doi">10.1002/mds.22473</idno>
<idno type="url">https://api-v5.istex.fr/document/E7D9C00B982C39FA601C49360BD62531C9418656/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000238</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000238</idno>
<idno type="wicri:Area/Istex/Curation">000238</idno>
<idno type="wicri:Area/Istex/Checkpoint">000735</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000735</idno>
<idno type="wicri:doubleKey">0885-3185:2009:Fox S:serotonin:and:parkinson</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:19412960</idno>
<idno type="wicri:Area/PubMed/Corpus">000E54</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E54</idno>
<idno type="wicri:Area/PubMed/Curation">000E54</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000E54</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000E54</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000E54</idno>
<idno type="wicri:Area/Ncbi/Merge">000A75</idno>
<idno type="wicri:Area/Ncbi/Curation">000A75</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000A75</idno>
<idno type="wicri:Area/Main/Merge">002112</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:09-0349961</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000525</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000767</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000418</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000418</idno>
<idno type="wicri:doubleKey">0885-3185:2009:Fox S:serotonin:and:parkinson</idno>
<idno type="wicri:Area/Main/Merge">002222</idno>
<idno type="wicri:Area/Main/Curation">001F59</idno>
<idno type="wicri:Area/Main/Exploration">001F59</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Serotonin and Parkinson's disease: On movement, mood, and madness</title>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorders Clinic, McL 7–421, University of Toronto, Toronto Western Hospital, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country>Canada</country>
<wicri:regionArea>MCL7.421, Movement Disorders Clinic, Toronto Western Hospital, 399 Bathurst Street, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chuang, Rosalind" sort="Chuang, Rosalind" uniqKey="Chuang R" first="Rosalind" last="Chuang">Rosalind Chuang</name>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorders Clinic, McL 7–421, University of Toronto, Toronto Western Hospital, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Brain, Imaging and Behavior – Systems Neuroscience, Toronto Western Research Institute, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2009-07-15">2009-07-15</date>
<biblScope unit="volume">24</biblScope>
<biblScope unit="issue">9</biblScope>
<biblScope unit="page" from="1255">1255</biblScope>
<biblScope unit="page" to="1266">1266</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">E7D9C00B982C39FA601C49360BD62531C9418656</idno>
<idno type="DOI">10.1002/mds.22473</idno>
<idno type="ArticleID">MDS22473</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>5‐HT</term>
<term>Affect (physiology)</term>
<term>Animals</term>
<term>Anxiety</term>
<term>Constipation</term>
<term>Depression</term>
<term>Dyskinesia</term>
<term>Dyskinesia, Drug-Induced</term>
<term>Humans</term>
<term>Mental Disorders (complications)</term>
<term>Mental Disorders (metabolism)</term>
<term>Mood</term>
<term>Movement (physiology)</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Psychosis</term>
<term>Serotonin</term>
<term>Serotonin (metabolism)</term>
<term>Serotonin Agents (adverse effects)</term>
<term>Serotonin Agents (therapeutic use)</term>
<term>anxiety</term>
<term>constipation</term>
<term>depression</term>
<term>dyskinesia</term>
<term>psychosis</term>
<term>serotonin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Serotonin Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Serotonin</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Mental Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Mental Disorders</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Affect</term>
<term>Movement</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Serotonin Agents</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Dyskinesia, Drug-Induced</term>
<term>Humans</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Angoisse anxiété</term>
<term>Constipation</term>
<term>Dyskinésie</term>
<term>Etat dépressif</term>
<term>Humeur</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
<term>Psychose</term>
<term>Sérotonine</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">An appreciation of the multiple roles that serotonin (5‐HT) may play in Parkinson's disease (PD) has increased in recent years. Early pathological studies in PD demonstrated nonselective reductions of 5‐HT in brain tissue but little correlation to comorbidities such as dyskinesia and mood disturbance. This, combined with treatment failures using serotonergic drugs in comparison to levodopa, meant the field was largely neglected until recently. The multitude of subtypes of 5‐HT receptors in the brain and an increased understanding of the potential function 5‐HT may play in modulating other neurotransmitter systems, including dopamine, GABA, and glutamate, have meant an expansion in efforts to develop potential serotonergic drugs for both motor and nonmotor symptoms in PD. However, several unanswered questions remain, and future studies need to focus on correlating changes in 5‐HT neurotransmission in both pathological and in vivo imaging studies with a full clinical phenotype. © 2009 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
<region><li>Ontario</li>
</region>
<settlement><li>Toronto</li>
</settlement>
<orgName><li>Université de Toronto</li>
</orgName>
</list>
<tree><country name="Canada"><region name="Ontario"><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
</region>
<name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<name sortKey="Chuang, Rosalind" sort="Chuang, Rosalind" uniqKey="Chuang R" first="Rosalind" last="Chuang">Rosalind Chuang</name>
<name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F59 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001F59 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:E7D9C00B982C39FA601C49360BD62531C9418656 |texte= Serotonin and Parkinson's disease: On movement, mood, and madness }}
This area was generated with Dilib version V0.6.29. |